New PET tracer could make pituitary tumor imaging more accessible

NCT ID NCT06584123

Recruiting now Diagnosis Sponsor: University of Cambridge Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study at the University of Cambridge is testing whether a new PET scan tracer called FET can locate pituitary tumors as well as the standard tracer, methionine. The study involves 20 adults with suspected pituitary adenomas who have already had a methionine PET scan. If FET works similarly, it could be easier to produce and distribute, potentially expanding access to this type of imaging.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-fluoro-ethyl-tyrosine (FET) PET tracer
What this could lead to: If FET works as well as the current tracer, it could make advanced pituitary tumor imaging more widely available, since FET is easier to produce and distribute.
What could go wrong: This is a very small pilot study with only 20 participants, so results may not apply to everyone. It is also testing a diagnostic tool, not a treatment, so it won't directly improve health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PITUITARY ADENOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pituitary gland adenoma Pituitary Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PITUITARY ADENOMA

Contacts and locations

Locations

Cambridge University Hospitals
RECRUITING

Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.